Seres Therapeutics (MCRB) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
August 3, 2021 7:00 AM EDTSER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021
SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future payments equal to 50% of profits
Microbiome analyses from SER-287 Phase 2b ulcerative colitis study anticipated in H2 2021
Continued clinical development progress with SER-155 and SER-301, next-generation rationally designed pipeline candidates
Conference call at 8:30 a.m. ET today
CAMBRIDGE,... More
